Entera Bio Ltd - Company Profile
Powered by 
All the data and insights you need on Entera Bio Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Entera Bio Ltd Strategy Report
- Understand Entera Bio Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Entera Bio Ltd (Entera Bio) is a biopharmaceutical company that specializes in the oral delivery of molecules and biologics. The company develops novel drug delivery platforms for oral delivery of large molecule protein active pharmaceutical ingredients. It offers pipeline products such as EB613 for the treatment of osteoporosis, EB612 for the treatment of hypoparathyroidism, GLP-2 for short bowel syndrome and hGH for GH deficiency. Entera Bio conducts clinical trials on its proprietary technology that allows oral delivery of large molecules and biologics while enhancing their absorption in the gastrointestinal tract. It operates in Israel and the US. Entera Bio is headquartered in Jerusalem, Israel.
Headquarters
Israel
Address
Hadassah / Jerusalem Bio, Park, 5th Floor, 9112002
Website
enterabio.com
Telephone
972 2 5327151
No of Employees
17
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ENTX (NASD)
EPS
XYZ
Net Income (2022)
XYZ
32%
(2022 vs 2021)
Market Cap*
$87.6M
Net Profit Margin (2021)
XYZ
-357.0%
(2022 vs 2021)
* As of and is in US$
Entera Bio Ltd premium industry data and analytics
Products and Services
| Products | Services |
|---|---|
| EB612 (to Treat Hypoparathyroidism) | Clinical Trials Services |
| EB613 (to Treat Osteoporosis) | Drug Development Services |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In September, the company entered into an agreement with OPKO Biologics for the development of oral tablet formulations using Entera’s proprietary oral delivery technology. |
| 2022 | Contracts/Agreements | In October, the company announced FDA agreement for a single phase 3 clinical trial to support an NDA for EB613 for the treatment of Osteoporosis. |
| 2018 | Stock Listings/IPO | In January, the company postponed IPO of shares for US$141 million. |
Competitor Comparison
| Key Parameters | Entera Bio Ltd | Compugen Ltd | BioLineRx Ltd | Chemomab Therapeutics Ltd | Scinai Immunotherapeutics Ltd |
|---|---|---|---|---|---|
| Headquarters | Israel | Israel | Israel | Israel | Israel |
| City | Jerusalem | Holon | Modiin | Tel Aviv-Yafo | Jerusalem |
| State/Province | Jerusalem | Sharon (Netanya) | - | - | Jerusalem |
| No. of Employees | 17 | 68 | 79 | 20 | 33 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Gerald Lieberman | Chairman | Executive Board | 2019 | 76 |
| Miranda J Toledano | Director; Chief Executive Officer | Executive Board | 2022 | 46 |
| Dana Yaacov Garbeli | Chief Financial Officer | Senior Management | 2022 | 39 |
| Hillel Galitzer | Chief Operating Officer | Senior Management | 2014 | 44 |
| Arthur Santora | Chief Medical Officer | Senior Management | 2018 | 72 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer